---
title: Alnylam Pharmaceuticals (ALNY) — intrinsic value and fair price
canonical: https://sweetvaluelab.com/stocks/alny
ticker: ALNY
as_of: 2026-10-17
sector: Healthcare
industry: Biotechnology
---
# Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals (ALNY) closed at $231.83 on Oct 16, 2026, overvalued by 12% vs its model value of $207.11 (from a five-year discounted cash flow).

## Key figures

| Figure | Value |
| --- | ---: |
| Last close | $231.83 (Oct 16, 2026) |
| Model value (from a five-year discounted cash flow) | $207.11 |
| Price vs model | overvalued by 12% vs model |
| Range of that model | $111.86 – $383.15 |
| Market value | $31.0B |
| P/E (fiscal 2025) | 99.5 |
| Net margin (fiscal 2025) | 8.4% |
| Free cash flow (fiscal 2025) | $465.4M |
| Dividend yield (trailing twelve months) | 0.00% |
| Beta | 0.27 |
| Cost of capital (WACC) | 7.43% |
| Business classification | High Growth (High revenue growth (~43% recent), Moderate margins (8% net margin), Highly cyclical earnings) |

## On the stock lists

| List | Place | Figure | Page |
| --- | ---: | ---: | --- |
| Worst performing this year | #17 | −41.7% | https://sweetvaluelab.com/lists/worst-performing-this-year |

## Valuation models

Each model's value per share and the role the engine gave it for this business. The headline above is one model's value; every other model is listed with its own, and each has a page of its own under the valuation. Computed Oct 17, 2026.

| Model | Role | Value per share | Low | High |
| --- | --- | ---: | ---: | ---: |
| DCF · Perpetuity growth · 5y | primary | $207.11 | $111.86 | $383.15 |
| DCF · Perpetuity growth · 10y | cross check | $255.74 | $139.20 | $491.06 |
| DCF · EBITDA exit · 5y | cross check | $209.46 | $160.55 | $266.85 |
| DCF · EBITDA exit · 10y | cross check | $257.97 | $187.89 | $350.55 |
| P/E · peers | cross check | $0.00 | $0.00 | $0.00 |
| P/E · own history | cross check | $0.00 | $0.00 | $0.00 |
| PEG | sanity check | $166.62 | $166.62 | $166.62 |
| EV/EBITDA · peers | cross check | $124.13 | $124.13 | $124.13 |
| EV/Revenue · peers | cross check | $401.84 | $374.56 | $1,855.16 |
| Earnings power value | cross check | $0.00 | $0.00 | $0.00 |

## Insider activity (SEC Form 4)

Past 90 days: 0 open-market buys ($0) and 1 open-market sale ($398,855); 10b5-1 plan sales included.

| Date | Insider | Relationship | Transaction | Shares | Value |
| --- | --- | --- | --- | ---: | ---: |
| Oct 2, 2026 | SUPRAN BRYAN | EVP, CLO and Secretary | Open-market sell | 1,758 | $398,855 |
| Sep 19, 2026 | Greenstreet Yvonne | Chief Executive Officer | Grant / award | 107 | $0 |
| Jun 1, 2026 | PYOTT DAVID E I | Director | Option/RSU exercise (10b5-1 plan) | 3,830 | $0 |
| Jun 1, 2026 | PYOTT DAVID E I | Director | Open-market sell (10b5-1 plan) | 921 | $274,190.9 |
| Jun 1, 2026 | PYOTT DAVID E I | Director | Open-market sell (10b5-1 plan) | 1,175 | $351,219.3 |

## Recent SEC filings

| Filed | Form | What | Filing |
| --- | --- | --- | --- |
| Jul 30, 2026 | 10-Q | Quarterly report | https://www.sec.gov/Archives/edgar/data/1178670/000117867026000062/alny-20260630.htm |
| Jul 30, 2026 | 8-K | 2.02 Results of Operations (Earnings); 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/1178670/000117867026000060/alny-20260730.htm |
| May 27, 2026 | 8-K | 5.02 Departure/Election of Directors or Officers; 5.07 Submission of Matters to a Shareholder Vote | https://www.sec.gov/Archives/edgar/data/1178670/000162828026038499/alny-20260520.htm |
| Apr 30, 2026 | 10-Q | Quarterly report | https://www.sec.gov/Archives/edgar/data/1178670/000162828026028605/alny-20260331.htm |
| Apr 30, 2026 | 8-K | 2.02 Results of Operations (Earnings); 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/1178670/000162828026028601/alny-20260430.htm |

## Superinvestors holding it (latest 13F)

| Manager | Quarter | Shares | Value |
| --- | --- | ---: | ---: |
| Dodge & Cox | 2026-06-30 | 1,955,393 | $588.6M |
| Bridgewater | 2026-06-30 | 99,584 | $30.0M |

2 tracked managers in all.

## About

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies i…

---

Source: https://sweetvaluelab.com/stocks/alny (SweetValueLab, free, no account). Prices and statements from Financial Modeling Prep; filings from SEC EDGAR. Research and educational data, not investment advice; nothing here is a recommendation to buy, sell or hold any security.